Clinical Trials on Diabetic Blood Glucose Monitoring in Russian Federation

Total 381 results

Eli Lilly and Company

Terminated

A Study of LY2599506 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, Spain, United States, Australia
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Sanofi

Completed

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients (RECOMMEND)

Diabetes Mellitus, Type 2

Algeria, Colombia, Egypt, Guatemala, India, Iran, Islamic Republic of, Lebanon, Mexico, Russian Federation, South Africa, Tunisia, Turkey, Ukraine, United Arab Emirates
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Macedonia, The Former Yugoslav Republic of, Russian Federation, Turkey, Croatia, Australia, Philippines
Pfizer

Completed

Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (FEENICS)

Diabetic Foot Ulcer

Canada, Greece, Austria, Finland, Poland, Sweden, Russian Federation, Norway, Spain, Italy, United Kingdom, Denmark, Lithuania, Belgium, Germany, Ukraine, Czechia
Novo Nordisk A/S

Completed

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Czech Republic, Poland
Hoffmann-La Roche

Completed

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Diabetes Mellitus Type 2

United States, Russian Federation, Mexico, Ukraine, Puerto Rico
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, United States, Australia, Hungary, Poland, Romania, Spain
Novo Nordisk A/S

Completed

Diabetes Attitudes Wishes and Needs (DAWN2)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare Professionals

Spain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
Eli Lilly and Company

Completed

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (IOOZ)

Diabetes Mellitus, Type 1

Russian Federation, United States, Australia, Greece, Argentina, Hungary, Brazil, Mexico, Romania
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Novo Nordisk A/S

Completed

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania, Slovakia, Israel, Saudi Arabia, India, Malaysia, Mexico, Russian Federation, Germany, Croatia, Poland, Serbia, Bulgaria, Canada, Slovenia, Sweden, Denmark, Hungary, Argentina, Austria, Finland, Lebanon, Czechia, Netherlands
Hoffmann-La Roche

Completed

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

Diabetes Mellitus Type 2

Australia, Hong Kong, Spain, United States, Mexico, Russian Federation, Guatemala, United Kingdom, Brazil
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Diabetes Mellitus, Type 2

Bulgaria, Estonia, Russian Federation, Ukraine, United Kingdom, Hungary, Poland, Romania
Novo Nordisk A/S

Completed

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Poland, Czech Republic
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
AstraZeneca
Parexel; PRA Health Sciences; Q2 Solutions; Covance Laboratories, Inc

Completed

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Type 2 Diabetes

United States, Israel, Hungary, Russian Federation, Mexico, Romania, United Kingdom
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Sanofi

Completed

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus (SAMS12)

Sleep Initiation and Maintenance Disorders

United States, France, Canada, Brazil, Russian Federation, Netherlands, Switzerland, Turkey, Malaysia, Taiwan, Czech Republic, Finland, Italy, Colombia, South Africa, Greece
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Boehringer Ingelheim

Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Philippines, Romania, Russian Federation, Ukraine
AstraZeneca
Eli Lilly and Company

Completed

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Taiwan, United Kingdom, Portugal, Spain, Netherlands, Croatia, Slovenia, Greece, Italy, Germany, Romania, Russian Federation
Boehringer Ingelheim

Completed

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Hypertension | Diabetic Nephropathies

Spain, Taiwan, Malaysia, Italy, Portugal, France, Czech Republic, Korea, Republic of, Russian Federation, Denmark, Germany, Slovakia, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (CONDOR)

Proliferative Diabetic Retinopathy

China, India, Japan, Russian Federation, Turkey, Canada, United States, Australia, Korea, Republic of, Brazil, Philippines, Puerto Rico, Taiwan, Argentina, Chile, Mexico
Eli Lilly and Company

Withdrawn

A Study in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Spain, Poland, Austria, Germany, Czech Republic, Russian Federation
Eli Lilly and Company

Completed

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Russian Federation, Poland, Spain, Mexico, Croatia, Denmark, India
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Boehringer Ingelheim

Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Diabetes Mellitus, Type 2

United States, Argentina, Hungary, India, Japan, Poland, Russian Federation
AstraZeneca
Quintiles, Inc.

Completed

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Type 2 Diabetes

United States, Korea, Republic of, India, Russian Federation, Brazil, Mexico, South Africa, Philippines
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus (ELEMENT 5)

Diabetes Mellitus, Type 2

India, Turkey, United States, Puerto Rico, Taiwan, Korea, Republic of, Russian Federation
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Patients With Type 2 Diabetes

Diabetes Mellitus Type 2

Italy, Hong Kong, Romania, Greece, United States, Mexico, Serbia, Russian Federation
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Novo Nordisk A/S

Completed

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Argentina, Slovakia, Greece, South Africa, Australia
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Diabetes Mellitus Type 2

Australia, Mexico, Taiwan, United States, Israel, Russian Federation, Slovakia, Ukraine, Guatemala, Peru, Romania
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Hypertension | Metabolic Syndrome

Spain, Italy, Russian Federation, Norway, France, Germany
Phenomix
Forest Laboratories

Terminated

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Chromaderm, Inc.

Completed

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Diabetic Retinopathy

United States, Canada, France, Denmark, Australia, Netherlands, Taiwan, Spain, Italy, Germany, Portugal, United Kingdom, Russian Federation, Poland, India, Brazil, Mexico
ActivX Biosciences, Inc.
Kyorin Pharmaceutical Co.,Ltd

Completed

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone (Synergy104)

Type 2 Diabetes

United States, Poland, Argentina, Russian Federation, Czech Republic, South Africa, Guatemala
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Denmark, Netherlands, Norway, South Africa, Finland, France, Spain, Former Serbia and Montenegro, Sweden
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)

Diabetes Mellitus, Type 2

Spain, United States, India, Czechia, Canada, Latvia, United Kingdom, Portugal, Serbia, Poland, Romania, Brazil, Russian Federation, Slovakia, Bulgaria, Mexico, Germany, Greece, Israel
Hoffmann-La Roche

Completed

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, Hong Kong, Romania, United States, Japan, Russian Federation, Spain, Canada, Germany, Latvia, Mexico, Brazil

Clinical Trials on Diabetic Blood Glucose Monitoring in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations